"Selective laser trabeculoplasty should not only be considered an effective and safe alternative to medications as a ...

Glaucoma is a lifelong eye disease that requires regular treatment. For many, it can be controlled by a daily eye drop ...

SpyGlass Pharma released 18-month follow-up data highlighting the potential of its (IOL)-based drug delivery platform.

Fintel reports that on October 16, 2024, Scotiabank initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Sector ...

Other pain relievers may be less dangerous. Aspirin is also an NSAID, but experts think that it's safer for people with hypertension. Acetaminophen is a different type of painkiller that doesn't ...

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024Topline clinical data from SOL-1 are now expected in Q4 2025BEDFORD, ...

Ocular Therapeutix's Elutyx drug delivery platform offers sustained long-term effects. See why OCUL stock is a Buy.

Ocular Therapeutix, Inc. (NASDAQ:OCUL,“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for ...

Follow the Company on its website, LinkedIn, or X. The Ocular Therapeutix logo and DEXTENZA ® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular ...

NICE has recommended latanoprost–netarsudil as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients. This approval marks a significant milestone as Yuvanci becomes the only single tablet option available for PAH ...